Role of real-world data in assessing cardiac toxicity after lung cancer radiotherapy
Name:
35928875.pdf
Size:
804.7Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Abravan, AzadehPrice, Gareth J
Banfill, Kathryn
Marchant, Thomas E
Craddock, Matthew
Wood, Joe
Aznar, Marianne Camille
McWilliam, Alan
van Herk, Marcel
Faivre-Finn, Corinne
Affiliation
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United KingdomIssue Date
2022
Metadata
Show full item recordAbstract
Radiation-induced heart disease (RIHD) is a recent concern in patients with lung cancer after being treated with radiotherapy. Most of information we have in the field of cardiac toxicity comes from studies utilizing real-world data (RWD) as randomized controlled trials (RCTs) are generally not practical in this field. This article is a narrative review of the literature using RWD to study RIHD in patients with lung cancer following radiotherapy, summarizing heart dosimetric factors associated with outcome, strength, and limitations of the RWD studies, and how RWD can be used to assess a change to cardiac dose constraints.Citation
Abravan A, Price G, Banfill K, Marchant T, Craddock M, Wood J, et al. Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy. Frontiers in oncology. 2022;12:934369. PubMed PMID: 35928875. Pubmed Central PMCID: PMC9344971. Epub 2022/08/06. eng.Journal
Frontiers in OncologyDOI
10.3389/fonc.2022.934369PubMed ID
35928875Additional Links
https://dx.doi.org/10.3389/fonc.2022.934369Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3389/fonc.2022.934369